FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023131161> ?p ?o ?g. }

• W2023131161 endingPage "229" @default.
• W2023131161 startingPage "221" @default.
• W2023131161 abstract "The newly available iron chelator deferasirox (Exjade, Novartis) is expected to provide better long-term clinical outcomes and improved quality of life for patients with thalassemia than its predecessor, deferoxamine (Desferal, Novartis), because of its oral tablet form.We used the Markov model to estimate total additional lifetime costs and quality-adjusted life years (QALYs) gained with deferasirox versus deferoxamine in patients with transfusion-dependent thalassemia. Patients were assumed to be 2 years of age at initiation of chelation therapy. Clinical outcomes in terms of morbidity and mortality from associated complications and life expectancy for the study population were estimated using the databases of the Bureau of National Health Insurance and the Health and Vital Statistics of Taiwan. Treatment costs were based on analyses of health insurance claims for patients with transfusion-dependent thalassemia. Utilities in terms of quality of life were also included in the model. The incremental cost-utility ratio of deferasirox versus deferoxamine was defined by the ratio of the difference in expected lifetime costs to the difference in QALYs. One-way sensitivity analyses were performed to examine the robustness of the results to key assumptions.Patients treated with deferasirox are expected to experience a lower incidence of associated complications and obtain 2.3 QALYs (discounted) at an additional lifetime cost of US$36,291 per patient (US$15,596 per QALY). Sensitivity analyses showed that the unit drug cost of deferasirox had the greatest impact on the incremental cost-utility ratio. In addition, the incremental cost-utility ratio will increase by delaying the starting age (2 years of age in our study) of chelation therapy.Compared with infusional deferoxamine, oral deferasirox improved clinical outcomes and quality of life in terms of iron chelation in transfusion-dependent patients with thalassemia at a reasonable cost from a healthcare perspective." @default.
• W2023131161 created "2016-06-24" @default.
• W2023131161 creator A5016530655 @default.
• W2023131161 creator A5028421339 @default.
• W2023131161 creator A5028489918 @default.
• W2023131161 creator A5041418118 @default.
• W2023131161 creator A5048928275 @default.
• W2023131161 creator A5057937159 @default.
• W2023131161 creator A5065572900 @default.
• W2023131161 creator A5078054883 @default.
• W2023131161 creator A5086609279 @default.
• W2023131161 date "2013-04-01" @default.
• W2023131161 modified "2023-09-27" @default.
• W2023131161 title "A pharmaco-economic evaluation of deferasirox for treating patients with iron overload caused by transfusion-dependent thalassemia in Taiwan" @default.
• W2023131161 cites W1514932744 @default.
• W2023131161 cites W1974935155 @default.
• W2023131161 cites W1983330639 @default.
• W2023131161 cites W1983607584 @default.
• W2023131161 cites W1998551984 @default.
• W2023131161 cites W2004947609 @default.
• W2023131161 cites W2006132037 @default.
• W2023131161 cites W2011000634 @default.
• W2023131161 cites W2022595661 @default.
• W2023131161 cites W2037319363 @default.
• W2023131161 cites W2055148131 @default.
• W2023131161 cites W2055225978 @default.
• W2023131161 cites W2062919513 @default.
• W2023131161 cites W2078904403 @default.
• W2023131161 cites W2110713267 @default.
• W2023131161 cites W2119692077 @default.
• W2023131161 cites W2122529949 @default.
• W2023131161 cites W2135342762 @default.
• W2023131161 cites W2144154299 @default.
• W2023131161 cites W2146921545 @default.
• W2023131161 cites W2150712216 @default.
• W2023131161 cites W2164654252 @default.
• W2023131161 cites W2170518980 @default.
• W2023131161 cites W4211017378 @default.
• W2023131161 cites W4237272940 @default.
• W2023131161 doi "https://doi.org/10.1016/j.jfma.2011.08.020" @default.
• W2023131161 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23537869" @default.
• W2023131161 hasPublicationYear "2013" @default.
• W2023131161 type Work @default.
• W2023131161 sameAs 2023131161 @default.
• W2023131161 citedByCount "13" @default.
• W2023131161 countsByYear W20231311612012 @default.
• W2023131161 countsByYear W20231311612013 @default.
• W2023131161 countsByYear W20231311612014 @default.
• W2023131161 countsByYear W20231311612015 @default.
• W2023131161 countsByYear W20231311612017 @default.
• W2023131161 countsByYear W20231311612019 @default.
• W2023131161 countsByYear W20231311612020 @default.
• W2023131161 countsByYear W20231311612021 @default.
• W2023131161 countsByYear W20231311612022 @default.
• W2023131161 crossrefType "journal-article" @default.
• W2023131161 hasAuthorship W2023131161A5016530655 @default.
• W2023131161 hasAuthorship W2023131161A5028421339 @default.
• W2023131161 hasAuthorship W2023131161A5028489918 @default.
• W2023131161 hasAuthorship W2023131161A5041418118 @default.
• W2023131161 hasAuthorship W2023131161A5048928275 @default.
• W2023131161 hasAuthorship W2023131161A5057937159 @default.
• W2023131161 hasAuthorship W2023131161A5065572900 @default.
• W2023131161 hasAuthorship W2023131161A5078054883 @default.
• W2023131161 hasAuthorship W2023131161A5086609279 @default.
• W2023131161 hasBestOaLocation W20231311612 @default.
• W2023131161 hasConcept C112930515 @default.
• W2023131161 hasConcept C126322002 @default.
• W2023131161 hasConcept C159110408 @default.
• W2023131161 hasConcept C177713679 @default.
• W2023131161 hasConcept C187212893 @default.
• W2023131161 hasConcept C2776517179 @default.
• W2023131161 hasConcept C2776672577 @default.
• W2023131161 hasConcept C2777799968 @default.
• W2023131161 hasConcept C2777940137 @default.
• W2023131161 hasConcept C2779951463 @default.
• W2023131161 hasConcept C2781053155 @default.
• W2023131161 hasConcept C2908647359 @default.
• W2023131161 hasConcept C3019080777 @default.
• W2023131161 hasConcept C64332521 @default.
• W2023131161 hasConcept C71924100 @default.
• W2023131161 hasConcept C99454951 @default.
• W2023131161 hasConceptScore W2023131161C112930515 @default.
• W2023131161 hasConceptScore W2023131161C126322002 @default.
• W2023131161 hasConceptScore W2023131161C159110408 @default.
• W2023131161 hasConceptScore W2023131161C177713679 @default.
• W2023131161 hasConceptScore W2023131161C187212893 @default.
• W2023131161 hasConceptScore W2023131161C2776517179 @default.
• W2023131161 hasConceptScore W2023131161C2776672577 @default.
• W2023131161 hasConceptScore W2023131161C2777799968 @default.
• W2023131161 hasConceptScore W2023131161C2777940137 @default.
• W2023131161 hasConceptScore W2023131161C2779951463 @default.
• W2023131161 hasConceptScore W2023131161C2781053155 @default.
• W2023131161 hasConceptScore W2023131161C2908647359 @default.
• W2023131161 hasConceptScore W2023131161C3019080777 @default.
• W2023131161 hasConceptScore W2023131161C64332521 @default.
• W2023131161 hasConceptScore W2023131161C71924100 @default.
• W2023131161 hasConceptScore W2023131161C99454951 @default.
• W2023131161 hasIssue "4" @default.

• next